Costs implications of pneumococcal vaccination of adults aged 30-60 with a recent diagnosis of diabetes.
Costs implications of pneumococcal vaccination of adults aged 30-60 with a recent diagnosis of diabetes.
复制标题
DOI：
10.1016/j.vaccine.2020.11.060
复制
发表时间：
2021-02-22
期刊：
影响因子：
5.5
通讯作者：
Pike, Jamison
中科院分区：
文献类型：
--
作者：
Hutton, David W.;McCullough, Jeffrey S.;Prosser, Lisa;Ye, Wen;Herman, William H.;Zhang, Ping;Pilishvili, Tamara;Pike, Jamison
23价肺炎球菌多糖疫苗被常规推荐用于成人糖尿病患者，但对这一建议的依从性以及这些成人接种疫苗如何影响与肺炎球菌疾病相关的成本知之甚少。我们使用来自商业保险索赔数据集的数据来检查2005-2014年间新诊断为糖尿病的非老年人和未诊断为糖尿病的成年人。我们检查了肺炎球菌多糖疫苗接种率以及疫苗接种与肺炎球菌疾病成本之间的关系，比较了诊断为糖尿病和未诊断为糖尿病的人的结果。在30-60岁的成年人中，肺炎球菌多糖疫苗的总体接种率<1%/年。成人糖尿病患者肺炎球菌多糖疫苗接种率较高。肺炎球菌多糖疫苗接种率从2005年的每年2.9%增加到2014年的每年6.0%。在倾向评分匹配数据集上使用两部分差异中差异模型，肺炎球菌多糖疫苗接种可使糖尿病患者在接种疫苗前两年至接种后两年的人均肺炎球菌疾病成本降低90.54美元[95% CI: 183.59美元，- 2.49美元，（p=0.056）]。非老年糖尿病患者的肺炎球菌多糖疫苗接种率虽低，但呈上升趋势。肺炎球菌多糖疫苗接种对降低该人群肺炎球菌疾病的总体成本有一定影响。
The 23-valent pneumococcal polysaccharide vaccine is routinely recommended for adults with diabetes, but little is known about adherence to this recommendation and how vaccination of these adults affects costs related to pneumococcal disease. We used data from a commercial insurance claims dataset to examine a cohort of non-elderly adults with a new diagnosis of diabetes and adults with no diagnosis of diabetes from 2005–2014. We examined rates of pneumococcal polysaccharide vaccination and the relationship between vaccination and pneumococcal disease costs, comparing results for persons with a diagnosis of diabetes and those with no diagnosis of diabetes. Overall rates of pneumococcal polysaccharide vaccination among adults 30–60 years old were <1%/year. Rates of pneumococcal polysaccharide vaccination were higher for adults with diabetes. Pneumococcal polysaccharide vaccination rates more than doubled from 2.9% per year in 2005 to 6.0% per year in 2014 for adults vaccinated during the same year as their diabetes diagnosis. Using a two-part differences-in-differences model on a propensity-score matched dataset, pneumococcal polysaccharide vaccination may reduce average annual per-person pneumococcal disease costs by $90.54 [95% CI: $183.59, −$2.49, (p=0.056)] in persons with diabetes from two years before to two years after vaccination. Non-elderly adults with diabetes have low but rising rates of pneumococcal polysaccharide vaccination. Pneumococcal polysaccharide vaccination has a modest impact reducing overall costs of pneumococcal disease in this population.
登录
查看更多内容
DOI：
10.1016/s1473-3099(06)70466-2
发表时间：
2006-05
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Brundage JF
通讯作者：
Brundage JF
影响因子：
5.7
作者：
Stoecker, Charles;Kim, Lindsay;Pilishvili, Tamara
通讯作者：
Pilishvili, Tamara
影响因子：
5.5
作者：
Cho, Bo-Hyun;Stoecker, Charles;Moore, Matthew R.
通讯作者：
Moore, Matthew R.
影响因子：
5.5
作者：
Smith, Kenneth J.;Nowalk, Mary Patricia;Zimmerman, Richard K.
通讯作者：
Zimmerman, Richard K.
DOI：
10.1056/nejmoa1500245
发表时间：
2015-07-30
期刊：
The New England journal of medicine
影响因子：
--
作者：
Jain S;Self WH;Wunderink RG;Fakhran S;Balk R;Bramley AM;Reed C;Grijalva CG;Anderson EJ;Courtney DM;Chappell JD;Qi C;Hart EM;Carroll F;Trabue C;Donnelly HK;Williams DJ;Zhu Y;Arnold SR;Ampofo K;Waterer GW;Levine M;Lindstrom S;Winchell JM;Katz JM;Erdman D;Schneider E;Hicks LA;McCullers JA;Pavia AT;Edwards KM;Finelli L;CDC EPIC Study Team
通讯作者：
CDC EPIC Study Team